Highlighted PresentationsPharmacologyAntiplatelet

SOLACI-SBHCI 2023 | Is very short DAPT safe in HBR patients undergoing complex PCI – Dr. Marco Valgimigli

solaci
solaci
483
0

Read the most outstanding articles from SOLACI-SBHCI 2023 Congress.

In this case, check the presentation by Dr. Marco Valgimigli, entitled “Is very short DAPT safe in HBR patients undergoing complex PCI”

Marco-valgimigli-solaci-sbhci-2023

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Previous article
SOLACI-SBHCI 2023 | Acute pulmonary embolysmworkflow: Patient Screening & Endovascular treatment indications – Dr. João Luiz Frighetto
Next article
Moderate Aortic Stenosis: We Should Start Assessing It More Thoroughly
solaci
solaci

More articles by this author

How real are the adverse effects of statins? Evidence from randomized clinical trials

Dr. Juan Manuel Pérez - 0
The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects included in prescribing information,...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Dr. Andrés Rodríguez - 0
Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Dr. Omar Tupayachi - 0
Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

Other

How real are the adverse effects of statins? Evidence from randomized clinical trials

The safety of statins continues to be a subject of debate, partly due to the extensive list of adverse effects...
Dr. Juan Manuel Pérez -
SOLACI Sessionsspot_img

Recent Articles

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Dr. Juan Manuel Pérez - 0
Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

OCT- and IVUS-Guided Coronary Angioplasty in Acute Coronary Syndrome: Long-Term Clinical Outcomes

Dr. Andrés Rodríguez - 0
Percutaneous coronary angioplasty (PCI) in patients with acute coronary syndrome (ACS) has reduced mortality in the acute phase. However, recurrent ACS and target vessel...

One-Year Results of ENCIRCLE: Percutaneous Mitral Valve Replacement in Patients Ineligible for Surgery or TEER

Dr. Omar Tupayachi - 0
Symptomatic mitral regurgitation (MR) in patients who are not candidates for surgery or transcatheter edge-to-edge repair (TEER) remains a highly complex clinical scenario associated...